RT Journal Article
SR Electronic
T1 Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.25.20027664
DO 10.1101/2020.02.25.20027664
A1 Guan, Wei-jie
A1 Liang, Wen-hua
A1 Zhao, Yi
A1 Liang, Heng-rui
A1 Chen, Zi-sheng
A1 Li, Yi-min
A1 Liu, Xiao-qing
A1 Chen, Ru-chong
A1 Tang, Chun-li
A1 Wang, Tao
A1 Ou, Chun-quan
A1 Li, Li
A1 Chen, Ping-yan
A1 Sang, Ling
A1 Wang, Wei
A1 Li, Jian-fu
A1 Li, Cai-chen
A1 Ou, Li-min
A1 Cheng, Bo
A1 Xiong, Shan
A1 Ni, Zheng-yi
A1 Hu, Yu
A1 Xiang, Jie
A1 Liu, Lei
A1 Shan, Hong
A1 Lei, Chun-liang
A1 Peng, Yi-xiang
A1 Wei, Li
A1 Liu, Yong
A1 Hu, Ya-hua
A1 Peng, Peng
A1 Wang, Jian-ming
A1 Liu, Ji-yang
A1 Chen, Zhong
A1 Li, Gang
A1 Zheng, Zhi-jian
A1 Qiu, Shao-qin
A1 Luo, Jie
A1 Ye, Chang-jiang
A1 Zhu, Shao-yong
A1 Cheng, Lin-ling
A1 Ye, Feng
A1 Li, Shi-yue
A1 Zheng, Jin-ping
A1 Zhang, Nuo-fu
A1 Zhong, Nan-shan
A1 He, Jian-xing
YR 2020
UL http://medrxiv.org/content/early/2020/02/27/2020.02.25.20027664.abstract
AB Objective: To evaluate the spectrum of comorbidities and its impact on the clinical outcome in patients with coronavirus disease 2019 (COVID-19). Design: Retrospective case studies Setting: 575 hospitals in 31 province/autonomous regions/provincial municipalities across China Participants: 1,590 laboratory-confirmed hospitalized patients. Data were collected from November 21st, 2019 to January 31st, 2020. Main outcomes and measures: Epidemiological and clinical variables (in particular, comorbidities) were extracted from medical charts. The disease severity was categorized based on the American Thoracic Society guidelines for community-acquired pneumonia. The primary endpoint was the composite endpoints, which consisted of the admission to intensive care unit (ICU), or invasive ventilation, or death. The risk of reaching to the composite endpoints was compared among patients with COVID-19 according to the presence and number of comorbidities. Results: Of the 1,590 cases, the mean age was 48.9 years. 686 patients (42.7%) were females. 647 (40.7%) patients were managed inside Hubei province, and 1,334 (83.9%) patients had a contact history of Wuhan city. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints. 399 (25.1%) reported having at least one comorbidity. 269 (16.9%), 59 (3.7%), 30 (1.9%), 130 (8.2%), 28 (1.8%), 24 (1.5%), 21 (1.3%), 18 (1.1%) and 3 (0.2%) patients reported having hypertension, cardiovascular diseases, cerebrovascular diseases, diabetes, hepatitis B infections, chronic obstructive pulmonary disease, chronic kidney diseases, malignancy and immunodeficiency, respectively. 130 (8.2%) patients reported having two or more comorbidities. Patients with two or more comorbidities had significantly escalated risks of reaching to the composite endpoint compared with those who had a single comorbidity, and even more so as compared with those without (all P<0.05). After adjusting for age and smoking status, patients with COPD (HR 2.681, 95%CI 1.424-5.048), diabetes (HR 1.59, 95%CI 1.03-2.45), hypertension (HR 1.58, 95%CI 1.07-2.32) and malignancy (HR 3.50, 95%CI 1.60-7.64) were more likely to reach to the composite endpoints than those without. As compared with patients without comorbidity, the HR (95%CI) was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61-4.17) among patients with two or more comorbidities. Conclusion: Comorbidities are present in around one fourth of patients with COVID-19 in China, and predispose to poorer clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFUNDING: Supported by National Health Commission, Department of Science and Technology of Guangdong Province. The funder had no role in the conduct of the study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData would be available upon request to Prof Zhong (nanshan@vip.163.com)